Adaptive Biotechnologies (ADPT) is back in focus after raising full year 2026 revenue guidance for its Minimal Residual Disease (MRD) business alongside its latest quarterly earnings release.

The raised MRD revenue guidance and recent earnings update appear to have coincided with a sharp shift in sentiment toward Adaptive Biotechnologies, with the stock showing a 90 day share price return of 86.72% and a 1 year total shareholder return of 109.46% from a low base.

If this kind of renewed interest in healthcare AI is on your radar, it could be a good moment to see what else is moving through our 43 healthcare AI stocks

Adaptive Biotechnologies now sits between two stories. One points to raised MRD guidance and growing sales. The other points to ongoing losses and sentiment chasing healthcare AI. Which of those is driving the current valuation?

Most Popular Narrative: 14.2% Overvalued

At a last close of $25.45 versus a narrative fair value of $22.29, Adaptive Biotechnologies is framed as fully pricing in a lot of future execution.

Marked improvement in profitability, with the MRD segment now EBITDA positive and company-wide cash burn improving 36% year-over-year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise.

Want to see what sits behind that shift to operating leverage and the higher valuation multiple? The most followed narrative leans on specific revenue, margin and earnings paths that are not obvious from the headline numbers.

Result: Fair Value of $22.29 (OVERVALUED)

However, there is still clear execution risk for Adaptive Biotechnologies, with ongoing net losses and heavy reliance on a small group of key partnerships that could shift over time.

Next Steps

If the mixed sentiment around Adaptive Biotechnologies has you thinking, now is a good time to look through the fundamentals yourself and move quickly. You can then weigh any potential upside or downside by reviewing the 2 key rewards

Looking for more investment ideas beyond Adaptive Biotechnologies?

Before you move on, give yourself an edge by lining up a few more stocks that fit your style so you are not reacting after the big moves start.

• Start with potential value opportunities and see which companies currently look mispriced with the 51 high quality undervalued stocks
• Secure your income stream by scanning for companies that combine higher yields with resilient profiles through the 9 dividend fortresses
• Strengthen the quality of your watchlist by focusing on companies with robust financial footing using the solid balance sheet and fundamentals stocks screener (48 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.